3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase NA
5
Phase 2/3
4
Phase 1/2
4
Phase 1
3
Phase 3
1
Status
Recruiting
4
Not yet recruiting
1
Sponsor Class
OTHER
4
Study Type
Interventional
4
Sponsor
Cancer Type
Lymphoid
4
Other hematologic neoplasm
3
Dermatologic
2
CNS
2
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
23
Carcinoma, Non-Small-Cell Lung
15
Prostatic Neoplasms
14
Stomach Neoplasms
12
Colorectal Neoplasms
12
Breast Neoplasms
12
Pancreatic Neoplasms
11
Leukemia, Myeloid, Acute
10
Neoplasm Metastasis
9
Lung Neoplasms
9
Hematologic Neoplasms
9
Head and Neck Neoplasms
9
Endometrial Neoplasms
9
Carcinoma, Hepatocellular
9
Squamous Cell Carcinoma of Head and Neck
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Ovarian Neoplasms
8
Myasthenia Gravis
7
Melanoma
7
Uterine Cervical Neoplasms
6
Recurrence
6
Rectal Neoplasms
6
Neoplasms by Site
6
Neoplasms by Histologic Type
6
Lymphoma
6
Leukemia
6
Urinary Bladder Neoplasms
5
Neoplasms, Plasma Cell
5
Infections
5
Colonic Neoplasms
5
Interventions
entrectinib
2
atezolizumab
2
alectinib
2
pertuzumab
1
cobimetinib
1
capmatinib
1
Vemurafenib
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recruiting
×
Lymphoproliferative Disorders
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT05770102
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled